Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA 180-Day "Triggering Period" Favored By FTC, Opposed By Industry

This article was originally published in The Tan Sheet

Executive Summary

FDA's proposed implementation of a 180-day "triggering period" for ANDA exclusivity is supported in comments submitted by the Federal Trade Commission, but opposed by Bristol-Myers Squibb, the Pharmaceutical Research & Manufacturers of America and the Generic Pharmaceutical Industry Association.
Advertisement

Related Content

Exclusivity ruling
Exclusivity ruling
Exclusivity ruling
Leiner True Rhapsody Women's Energy Bars Shipping In March
Leiner True Rhapsody Women's Energy Bars Shipping In March
Leiner True Rhapsody Women's Energy Bars Shipping In March
180-Day Exclusivity Must Begin Within 180-Day "Triggering Period" - FDA
180-Day Exclusivity Must Begin Within 180-Day "Triggering Period" - FDA
Novopharm Entitled To OTC Ranitidine Generic Exclusivity - Federal Judge
Generic exclusivity "successful defense" removal is anticompetitive -- NAPM.

Topics

Advertisement
UsernamePublicRestriction

Register

PS090578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel